The VDRL test, short for Venereal Disease Research Laboratory test, is a blood test used to screen for syphilis. It works by detecting antibodies your immune system produces in response to the infection rather than detecting the syphilis-causing bacterium itself. Because of this indirect approach, a reactive (positive) VDRL result always requires a second, confirmatory test before a syphilis diagnosis is made.
How the VDRL Test Works
When the bacterium that causes syphilis damages your cells, your body releases fatty substances called lipids. Your immune system then produces antibodies against those lipids. The VDRL test looks for these specific antibodies, sometimes called reagin antibodies.
During the test, a small sample of your blood serum is mixed with a solution containing cardiolipin, cholesterol, and lecithin on a glass slide. If the antibodies are present in your blood, the mixture will clump together, a reaction visible under a microscope. Clumping means the result is “reactive.” No clumping means it’s “nonreactive.” The test is classified as “nontreponemal” because it doesn’t detect antibodies against the syphilis bacterium directly. It detects the immune response to cell damage the bacterium causes.
What the Results Mean
A nonreactive result means no antibodies were detected. In most cases, this means you don’t have syphilis. However, the test can miss very early infections before your immune system has produced enough antibodies to trigger a reaction.
A reactive result means antibodies were found, but it does not confirm syphilis on its own. The result is reported as a titer, which is a number like 1:2, 1:8, or 1:32 that reflects how concentrated the antibodies are in your blood. The higher the titer, the more antibodies are present. A fourfold change in titer between two tests (for example, from 1:4 to 1:16) is considered clinically significant and can signal a new infection, reinfection, or treatment failure.
After successful treatment, titers typically decrease at least fourfold within 12 months, especially in people treated during the early stages of syphilis. In some cases, the test eventually becomes nonreactive altogether, particularly when treatment happens before the secondary stage of infection.
Why False Positives Happen
Because the VDRL test doesn’t look for the syphilis bacterium itself, other conditions can trigger a reactive result. These are called biological false positives. Recent infections, certain vaccinations, injection drug use, and autoimmune conditions like lupus can all cause your body to produce the same type of antibodies the test detects. Pregnancy is another well-known cause of false-positive VDRL results.
People who test reactive on the VDRL but nonreactive on a confirmatory test that targets syphilis-specific antibodies are classified as “biological false positive reactors.” This distinction matters because it means you don’t have syphilis, even though the initial screen suggested you might. It’s one of the main reasons the VDRL is never used alone to diagnose syphilis.
VDRL vs. RPR
The RPR (Rapid Plasma Reagin) test is the other widely used nontreponemal screening test for syphilis. Both work on similar principles, detecting the same type of antibodies. The key practical difference is that RPR results can be read without a microscope, making it easier to automate for high-volume labs. RPR titers also tend to run slightly higher than VDRL titers for the same patient, so results from the two tests can’t be directly compared. If you’re being monitored over time, your follow-up tests should use the same type of nontreponemal test each time.
Confirmatory Testing After a Reactive Result
A reactive VDRL always leads to a second test, this time a treponemal test that detects antibodies specifically targeting the syphilis bacterium. Common confirmatory tests include the TP-PA (T. pallidum particle agglutination) and FTA-ABS (fluorescent treponemal antibody absorption). If the confirmatory test is also reactive, syphilis is diagnosed. If the confirmatory test is nonreactive, the initial VDRL result was likely a false positive.
Some labs now use a “reverse sequence” algorithm, starting with a treponemal test first and then following up with a nontreponemal test like the VDRL or RPR. Either way, no single test is enough for diagnosis. The two-step process exists because nontreponemal tests are good for screening large populations quickly, while treponemal tests provide the specificity needed to confirm the infection.
The VDRL’s Role in Neurosyphilis
The VDRL has a unique role in diagnosing neurosyphilis, which occurs when syphilis spreads to the brain and spinal cord. In this case, the test is performed on cerebrospinal fluid (the fluid surrounding the brain and spinal cord) rather than blood. A reactive CSF-VDRL in someone with neurological symptoms is considered diagnostic of neurosyphilis.
The CSF-VDRL is extremely specific for neurosyphilis, with a specificity of 100% in clinical studies, meaning a positive result is highly reliable. Its sensitivity, however, is lower, around 86%. That means it misses roughly 1 in 7 cases. A nonreactive CSF-VDRL doesn’t fully rule out neurosyphilis, so additional testing and clinical judgment come into play when symptoms are present but the result is negative.
What to Expect During the Test
The VDRL is a standard blood draw. No fasting or special preparation is needed. A small sample of blood is taken from a vein in your arm, and results are typically available within a few days. The test is inexpensive and widely available, which is why it remains a common first-line screening tool for syphilis despite being developed decades ago. If your result is reactive, expect your provider to order a confirmatory treponemal test before discussing any treatment.